References
- Bowman M. A., Leiter E. H., Atkinson M. A. Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease. Immunology Today 1994; 15: 115–20
- Hanafusa T., Miyagawa J., Nakajima H., Tomita K., Kuwajima M., Matsuzawa Y., Tarui S. The NOD mouse. Diabetes Res. Clin. Prae. 1994; 24: 307–11
- Saravia-Fernandcz F., Durant S., elHasnaoui A., Dardenne M., Homo-Delarche F. Environmental and experimental procedures leading to variations in the incidence of diabetes in the nonobese diabetic (NOD) mouse. Autoimmunity 1996; 24: 113–21
- Schneider K., Laube H., Linn T. A diet enriched in protein accelerates diabetes manifestation in NOD mice. Acta Diabetologica 1996; 33: 236–40
- Formby B., Miller N., Garret R., Peterson C M. Effects of low-dose eyclosporine prophylaxis in nonobese diabetic mice. J. Pharm. Exp. Ther. 1987; 241: 1106–11
- Sai P., Rivereau A. S. Prevention of diabetes in the nonobese diabetic mouse by oral immunological treatments. Comparative efficiency of human insulin and two bacterial antigens, lipopolysacharide from Escherichia coli and glycoprotein extract from Klebsiella pneumoniae. Diabetes Mela. 1996; 22: 341–8
- Pearce R. B., Peterson C M. Studies of Concanavalin A in nonobese diabetic mice. 1. Prevention of insulin-dependent diabetes. J. Pharm. Exp. Ther. 1991; 258: 710–5
- Mukherjee B., Pearce R. B., Formby B., Peterson C M. Studies of Concanavalin A in nonobese diabetic mice. II. Lymphocyte tracking and phenotype responses. J. Pharm. Exp. Ther. 1991; 258: 716–21
- Gazda L. S., Baxter A. G., Lafferty K. J. Regulation of autoimmune diabetes: characteristics of non-islet-antigen specific therapies. Immunol. Cell Biol. 1996; 74: 401–7
- Meyers W. M. Leprosy. Dermatol. Climes 1992; 10: 73–9
- Szefler S. J. Anti-inflammatory drugs in the treatment of allergic disease. Med. Clin. North Am. 1992; 76: 953–75
- Coleman M. D. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. British J. Dermatol. 1993; 129: 507–13
- Berlow B. A., Liebhaber M. I., Dyer Z., Spiegel T. M. The effect of dapsone in steroid-dependent asthma. J. Allergy Clin, lmmun. 1991; 87: 710–5
- Peterson K. P., Van Hirtum M., Peterson C M. Dapsone decreases the cumulative incidence of diabetes in non-obese diabetic female mice. Proc. Soc. Exp. Med. Biol. 1997; 215: 262–6
- Dubuc P. U., Scott B. K., Peterson C M. Sex differences in glycated hemoglobin in diabetic and non-diabetic C57B1/6 mice. Diabetes Res. Clin. Prac. 1993; 21: 95–101
- Booth S. A., Moody C. E., Dahl M. V., Herron M. J., Nelson R. D. Dapsone suppresses integrin-mediated neutrophil adherence function. J. Invest. Dermatol. 1992; 98: 135–40
- Lang P. G., Jr. Sulfones and sulfonamides in dermatology today. J. Am. Acad. Dermatol. 1979; 1: 479–92
- Uetrecht J., Zahid N., Shear N. H., Biggar W. D. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. J. Pharm. Exp. Ther. 1988; 245: 274–9
- Weiss S. J. Tissue destruction by neutrophils. New Engl. J. Med. 1989; 320: 365–76
- Harrison J. E., Shultz J. Studies on the chlorinating activity of myeloperoxidase. J. Biol. Chem. 1976; 251: 1371–4
- Kettle A. J., Gedye C. A., Winterbourn C. C. Superoxide is an antagonist of anti-inflammatory drugs that inhibit hypochlorous acid production by myeloperoxidase. Biochem. Pharm. 1993; 45: 2003–10
- Shimada A., Charlton B., Taylor-Edwards C., Fathman C. G. Beta-cell destruction may be a late consequence of the autoimmune process in nonobese diabetic mice. Diabetes 1996; 45: 1063–7
- Jansen A., Rosmalen J. G., Homo-Delarche F., Dardenne M., Drexhage H. A. Effect of prophylactic insulin treatment on the number of ER-MP23+ macrophages in the pancreas of NOD mice. Is the prevention of diabetes based on beta-cell rest?. Journal of Autoimmunity 1996; 9: 341–8